Expects more pronounced impact from newly launched products as the year progresses. STELARA biosimilar competition to ...

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

Johnson & Johnson's (JNJ) fourth-quarter results topped market expectations while the healthcare products conglomerate anticipates results in 2025 to be higher than the previous year. The company sees ...

Prism Johnson Ltd. key Products/Revenue Segments include Cement, Sale of services, Other Operating Revenue and Scrap for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, the company has ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...

The agreement dismisses the state’s 2023 lawsuit and does not find that the investment firm violated any laws. “We’re pleased to resolve this matter,” a BlackRock spokesperson said.

Johnson & Johnson reported better-than-expected quarterly revenue and profit on higher sales of cancer drugs and some medical devices. But shares slipped 3.2% to $143.35 in Wednesday morning trading, ...

As all eyes in the PC world look to 2025 as the year of the great refresh, Lenovo North America President Ryan McCurdy said ...